Diabetic Gastroparesis - Pipeline Review, H1 2018

  • ID: 4464919
  • Drug Pipelines
  • 59 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • ETX Pharma Inc
  • Evoke Pharma Inc
  • Johnson & Johnson
  • Melinta Therapeutics Inc
  • Theravance Biopharma Inc
  • MORE
Diabetic Gastroparesis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2018, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 2 respectively.

Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • ETX Pharma Inc
  • Evoke Pharma Inc
  • Johnson & Johnson
  • Melinta Therapeutics Inc
  • Theravance Biopharma Inc
  • MORE
Introduction

The Publisher's Report Coverage

Diabetic Gastroparesis - Overview

Diabetic Gastroparesis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Diabetic Gastroparesis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Gastroparesis - Companies Involved in Therapeutics Development

Allergan Plc

ETX Pharma Inc

Evoke Pharma Inc

Johnson & Johnson

Melinta Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

Diabetic Gastroparesis - Drug Profiles

CEM-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metoclopramide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

renzapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-906 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

velusetrag hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Gastroparesis - Dormant Projects

Diabetic Gastroparesis - Discontinued Products

Diabetic Gastroparesis - Product Development Milestones

Featured News & Press Releases

Oct 27, 2017: Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti

Oct 23, 2017: Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti

Oct 04, 2017: Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference

Sep 12, 2017: Evoke Pharma Completes Dosing for Gimoti Comparative Exposure Pharmacokinetic Study

Sep 05, 2017: Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Aug 14, 2017: Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti

Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis

May 31, 2017: Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti

May 15, 2017: Evoke Pharma Provides Update on Gimoti

May 10, 2017: Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week

May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis

May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week

Apr 04, 2017: Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA

Mar 21, 2017: Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week

Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Diabetic Gastroparesis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Diabetic Gastroparesis - Pipeline by Allergan Plc, H1 2018

Diabetic Gastroparesis - Pipeline by ETX Pharma Inc, H1 2018

Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2018

Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H1 2018

Diabetic Gastroparesis - Pipeline by Melinta Therapeutics Inc, H1 2018

Diabetic Gastroparesis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Diabetic Gastroparesis - Pipeline by Theravance Biopharma Inc, H1 2018

Diabetic Gastroparesis - Dormant Projects, H1 2018

Diabetic Gastroparesis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Diabetic Gastroparesis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • ETX Pharma Inc
  • Evoke Pharma Inc
  • Johnson & Johnson
  • Melinta Therapeutics Inc
  • Takeda Pharmaceutical Co Ltd
  • Theravance Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll